Fresenius Medical Care AG (Fresenius Medical Care AG) 5-Year EBITDA Growth Rate

: -3.70% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Fresenius Medical Care AG's EBITDA per Share for the three months ended in Dec. 2023 was $1.64.

During the past 12 months, Fresenius Medical Care AG's average EBITDA Per Share Growth Rate was -6.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -8.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -3.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fresenius Medical Care AG was 22.40% per year. The lowest was -30.30% per year. And the median was 7.00% per year.

Competitive Comparison

For the Medical Care Facilities subindustry, Fresenius Medical Care AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresenius Medical Care AG 5-Year EBITDA Growth Rate Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Fresenius Medical Care AG's 5-Year EBITDA Growth Rate falls into.

Fresenius Medical Care AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Fresenius Medical Care AG (NYSE:FMS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Fresenius Medical Care AG 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FME:Italy FMEd:UK 0H9X:UK FME:Germany FMEA:Germany FME:Germany FME:Germany FMEA:Germany FME:Germany FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Helen Pring Giza

Board of Directors